Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Introduction Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lympha ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

It can be difficult to find out that you have acute lymphoblastic leukaemia (ALL). It’s normal to feel angry, sad, upset and shocked. You might worry about what will happen and how you will cope.

Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells ...